Clinical application of novel tumor biomarkers：prospects and challenges

doi:10.3969/j.issn.1673-8640.2023.04.001

Abstract

Abstract:

Early diagnosis and individualized precise treatment are the keys to improve the survival rate and the quality of life and prolong the survival time of cancer patients. In the recent years，with the development of liquid biopsy technology，more and more novel tumor biomarkers have been found，showing potential in tumor diagnosis，prognostic judgment and treatment monitoring，and some indicators have been put into clinical practice. Future researches should focus on solving the problems that hinder the clinical transformation of novel tumor biomarkers，and promote more liquid biopsy indicators with clinical application prospects to optimize the diagnosis and treatment process of cancer patients，thereby reducing their disease burden.

Key words: Tumor biomarker, Circulating tumor cell, Circulating tumor DNA methylation, Non-coding RNA, Extracellular matrix

CLC Number:

R446.1

GAO Feng. Clinical application of novel tumor biomarkers：prospects and challenges[J]. Laboratory Medicine, 2023, 38(4): 303-306.

References 33.

1.	IGNATIADIS M, SLEDGE G W, JEFFREY S S. Liquid biopsy enters the clinic-implementation issues and future challenges[J]. Nat Rev Clin Oncol, 2021, 18(5):297-312. DOI
2.	RING A, NGUYEN-STRÄULI B D, WICKI A, et al. Biology, vulnerabilities and clinical applications of circulating tumour cells[J]. Nat Rev Cancer, 2023, 23(2):95-111. DOI
3.	LUO H, WEI W, YE Z, et al. Liquid biopsy of methylation biomarkers in cell-free DNA[J]. Trends Mol Med, 2021, 27(5):482-500. DOI PMID
4.	SLACK F J, CHINNAIYAN A M. The role of non-coding rnas in oncology[J]. Cell, 2019, 179(5):1033-1055. DOI PMID
5.	FREZZETTI D, DE LUCA A, NORMANNO N. Extracellular matrix proteins as circulating biomarkers for the diagnosis of non-small cell lung cancer patients[J]. J Thorac Dis, 2019, 11(Suppl 9):S1252-S1256. DOI URL
6.	DENG Z, WU S, WANG Y, et al. Circulating tumor cell isolation for cancer diagnosis and prognosis[J]. EBioMedicine, 2022, 83:104237. DOI URL
7.	ALIX-PANABIÈRES C, PANTEL K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy[J]. Cancer Discov, 2016, 6(5):479-491. DOI URL
8.	KELLER L, PANTEL K. Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells[J]. Nat Rev Cancer, 2019, 19(10):553-567. DOI PMID
9.	WANG Y, KIM T H, FOULADDEL S, et al. PD-L1 expression in circulating tumor cells increases during radio(chemo)therapy and indicates poor prognosis in non-small cell lung cancer[J]. Sci Rep, 2019, 9(1):566. DOI PMID
10.	BIDARD F C, PEETERS D J, FEHM T, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer:a pooled analysis of individual patient data[J]. Lancet Oncol, 2014, 15(4):406-414. DOI URL
11.	SCHER H I, HELLER G, MOLINA A, et al. Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer[J]. J Clin Oncol, 2015, 33(12):1348-1355. DOI PMID
12.	HELLER G, MCCORMACK R, KHEOH T, et al. Circulating tumor cell number as a response measure of prolonged survival for metastatic castration-resistant prostate cancer:a comparison with prostate-specific antigen across five randomized phase Ⅲ clinical trials[J]. J Clin Oncol, 2018, 36(6):572-580.
13.	AHN J C, TENG P C, CHEN P J, et al. Detection of circulating tumor cells and their implications as a biomarker for diagnosis,prognostication,and therapeutic monitoring in hepatocellular carcinoma[J]. Hepatology, 2021, 73(1):422-436. DOI URL
14.	ZHANG W, LI N, LIN L, et al. Metabolism-based capture and analysis of circulating tumor cells in an open space[J]. Anal Chem, 2021, 93(18):6955-6960. DOI PMID
15.	KHOO B L, GRENCI G, JING T, et al. Liquid biopsy and therapeutic response:circulating tumor cell cultures for evaluation of anticancer treatment[J]. Sci Adv, 2016, 2(7):e1600274. DOI URL
16.	KANWAL R, GUPTA K, GUPTA S. Cancer epigenetics:an introduction[J]. Methods Mol Biol, 2015, 1238:3-25.
17.	SPAINHOUR J C, LIM H S, YI S V, et al. Correlation patterns between DNA methylation and gene expression in the cancer genome atlas[J]. Cancer Inform, 2019, 18:1176935119828776.
18.	MORAN S, MARTÍNEZ-CARDÚS A, SAYOLS S, et al. Epigenetic profiling to classify cancer of unknown primary:a multicentre,retrospective analysis[J]. Lancet Oncol, 2016, 17(10):1386-1395. DOI URL
19.	LAMB Y N, DHILLON S. Epi proColon^® 2.0 CE:a blood-based screening test for colorectal cancer[J]. Mol Diagn Ther, 2017, 21(2):225-232. DOI URL
20.	ZHANG C, YU W, WANG L, et al. DNA methylation analysis of the SHOX2 and RASSF1A panel in bronchoalveolar lavage fluid for lung cancer diagnosis[J]. J Cancer, 2017, 8(17):3585-3591. DOI PMID
21.	XIE Y, ZHANG Y, DU L, et al. Circulating long noncoding RNA act as potential novel biomarkers for diagnosis and prognosis of non-small cell lung cancer[J]. Mol Oncol, 2018, 12(5):648-658. DOI PMID
22.	JENIKE A E, HALUSHKA M K. MiR-21:a non-specific biomarker of all maladies[J]. Biomark Res, 2021, 9(1):18. DOI
23.	ASHIRBEKOV Y, ABAILDAYEV A, OMARBAYEVA N, et al. Combination of circulating miR-145-5p/miR-191-5p as biomarker for breast cancer detection[J]. PeerJ, 2020, 8:e10494. DOI URL
24.	NG E K, LI R, SHIN V Y, et al. Circulating microRNAs as specific biomarkers for breast cancer detection[J]. PLoS One, 2013, 8(1):e53141. DOI URL
25.	KARAMANOS N K, THEOCHARIS A D, PIPERIGKOU Z, et al. A guide to the composition and functions of the extracellular matrix[J]. FEBS J, 2021, 288(24):6850-6912. DOI PMID
26.	GIUSSANI M, TRIULZI T, SOZZI G, et al. Tumor extracellular matrix remodeling:new perspectives as a circulating tool in the diagnosis and prognosis of solid tumors[J]. Cells, 2019, 8(2):81. DOI URL
27.	ALASEEM A, ALHAZZANI K, DONDAPATI P, et al. Matrix metalloproteinases:a challenging paradigm of cancer management[J]. Semin Cancer Biol, 2019, 56:100-115. DOI URL
28.	NECULA L, MATEI L, DRAGU D, et al. Collagen family as promising biomarkers and therapeutic targets in cancer[J]. Int J Mol Sci, 2022, 23(20):12415. DOI URL
29.	MOON P G, LEE J E, CHO Y E, et al. Fibronectin on circulating extracellular vesicles as a liquid biopsy to detect breast cancer[J]. Oncotarget, 2016, 7(26):40189-40199. DOI URL
30.	RESOVI A, BANI M R, PORCU L, et al. Soluble stroma-related biomarkers of pancreatic cancer[J]. EMBO Mol Med, 2018, 10(8):e8741. DOI URL
31.	CHEN L, HUAN X, XIAO G H, et al. Osteopontin and its downstream carcinogenic molecules:regulatory mechanisms and prognostic value in cancer progression[J]. Neoplasma, 2022, 69(6):1253-1269. DOI URL
32.	WU M, CAO M, HE Y, et al. A novel role of low molecular weight hyaluronan in breast cancer metastasis[J]. FASEB J, 2015, 29(4):1290-1298. DOI PMID
33.	ZHANG G, LU R, WU M, et al. Colorectal cancer-associated-6 kDa hyaluronan serves as a novel biomarker for cancer progression and metastasis[J]. FEBS J, 2019, 286(16):3148-3163. DOI URL

[1]	SHEN Ximin, ZHANG Lei, QUAN Heng, NIU Ziguang, XIA Dongge, ZHANG Rulin. Clinical significance of serum lncRNA NEAT1 for multiple myeloma patients with kidney injury [J]. Laboratory Medicine, 2025, 40(1): 32-36.
[2]	ZHANG Xiaoke, CHU Yanrong, WANG Rong, CUI Facai. Serum lncRNA HAND2-AS1 expression in cervical cancer patients and its effect on proliferation，invasion and migration of cervical cancer Caski cells [J]. Laboratory Medicine, 2024, 39(5): 429-437.
[3]	FANG Dandong, CHENG Gang, HUANG Wei, LIU Xiaonan, MAO Jian, HOU Baosen, LIU Shimin. Expression of lncRNA SOX21-AS1 and miR-875-5p in glioma tissues and relationship with prognosis of patients [J]. Laboratory Medicine, 2024, 39(3): 209-214.
[4]	WANG Zhaohui, ZHENG Zhenlu, LI Ruina, MA Yuanyuan, XU Hui, WEI Zhenhong, JIA Yanjuan, QI Xiaoming, GAO Xiaoling. Study of latent tuberculosis infection mechanism of DosR antigen Rv2626c inducing macrophage activation through lncRNA MacORIS [J]. Laboratory Medicine, 2024, 39(10): 923-932.
[5]	ZHANG Feifei, WANG Jingwen, ZHANG Yuexin, ZHENG Dawei, MEN Xiang. Correlation between lncRNA MIR155HG and pulmonary function in patients with COPD and its auxiliary diagnosis value for AECODP [J]. Laboratory Medicine, 2024, 39(1): 31-36.
[6]	ZHOU Yunlan, SHEN Lisong. Clinical application and challenges of liquid biopsy biomarkers in non-small cell lung cancer [J]. Laboratory Medicine, 2023, 38(9): 807-811.
[7]	WANG Tengfei, CHEN Shan, AN Hebing, ZHOU Lei. Expressions and roles of lncRNA CRNDE and miR-384 in peripheral blood of patients with acute leukemia [J]. Laboratory Medicine, 2023, 38(7): 686-691.
[8]	ZHANG Min, WANG Binyu, CHI Weiqun, LIU Yu. Research progress of exosomal non-coding RNA as biomarkers for disease diagnosis [J]. Laboratory Medicine, 2023, 38(6): 594-598.
[9]	WU Jiong, HU Jiahua, SHI Meifang, LIU Tao, DAI Jie, LU Xinyi, ZOU Zheng. Research progress of biomarkers of prostate cancer [J]. Laboratory Medicine, 2023, 38(2): 190-195.
[10]	ZHOU Furong, LI Yanzhu, LIU Yonggan. Application of lncRNA SNP in colorectal cancer susceptibility prediction and prognosis assessment [J]. Laboratory Medicine, 2023, 38(12): 1206-1210.
[11]	GUO Shuang, LIU Hongli, LI Ya. Progression of migration and invasion-related miRNA and lncRNA in Epstein-Barr virus-associated gastric cancer [J]. Laboratory Medicine, 2023, 38(10): 987-996.
[12]	WANG Ruijuan, LI Chao, DUAN Lijuan, SHANG Miao, YANG Ruyu. Expression and clinical significance of lncRNA RBM5-AS1 in acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(1): 39-45.
[13]	WANG Yuqing, ZHANG Yue, XU Wen, CUI Zhongqi. Construction and clinical application of colon cancer prognostic risk model of ferroptosis-related lncRNA [J]. Laboratory Medicine, 2022, 37(8): 720-728.
[14]	LIU Xingqiang, NING Lifen, LI Lin, CHEN Zhongcheng. Correlation of lung cancer clinicopathological characteristics with FR⁺-CTC,ANXA2 and ProGRP [J]. Laboratory Medicine, 2022, 37(8): 735-740.
[15]	JI Ye, YUAN Xiaosun, ZHANG Lei, MA Huili, XUE Yongfei, LI Changsheng, ZHANG Jingwei, REN Zhonghai, ZHANG Tengfei. Expression of lncRNA HULC in papillary thyroid carcinoma tissues [J]. Laboratory Medicine, 2022, 37(7): 605-609.